 and instead have developed it for rheumatoid arthritis and it's approved in a number of other countries. But one of the main reasons that it was decided not to move forward in transplantation is that because we had only the current endpoint, we didn't see a way to show that our new innovative therapy was better than the current therapy. And the current therapy is relatively inexpensive and it's available generically.